Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Region Proposal Unveiled; Options Range From 11 To 50

Executive Summary

The Centers for Medicare & Medicaid Services wants to hear more discussion about ideas to make multi-state regions possible under the Medicare prescription drug benefit law

You may also be interested in...



Medicare Rx Implementing Regs Open For Comment

CMS' schedule for the Medicare prescription drug benefit implementing regulations will give the agency 15 weeks to review comments and finalize the rule before Inauguration Day

Medicare Rx Implementing Regs Open For Comment

CMS' schedule for the Medicare prescription drug benefit implementing regulations will give the agency 15 weeks to review comments and finalize the rule before Inauguration Day

Medicare Rx Regions Will Define Managed Care Market For “Next 20 Years”

HHS is likely to define 15-17 regions for the Medicare prescription drug benefit in regulations coming out this year, former Centers for Medicare & Medicaid Services Administrator Tom Scully said

Topics

UsernamePublicRestriction

Register

PS044392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel